EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Metabolic signature biomarkers for predicting the recurrence of urological cancers

Filipa Amaro, Márcia Carvalho, Maria de Lourdes Bastos, Paula Guedes de Pinho, Joana Pinto

Clinica Chimica Acta · 2023

DOI: 10.1016/j.cca.2023.117553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2023. Verfasst von Filipa Amaro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Por…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Prostatic Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A significant number of patients diagnosed with localized urological cancers experience relapse and disease progression after surgery. Hence, molecular markers for patient risk stratification are needed to improve the current management guidelines. This article critically reviews for the first time, to our knowledge, the promise of metabolomics-based approaches to identify metabolic signatures as candidate prognostic biomarkers to predict recurrences at the time of surgery in prostate cancer (PCa), bladder cancer (BCa), and renal cell carcinoma (RCC). Dysregulations in the levels of several tumoral, circulating, and excreted metabolites have been reported in PCa patients experiencing recurrence within 1.5 to 8 years of follow-up. The combination of these metabolic biomarkers with clinical parameters (e.g., pathological T stage, Gleason score) has shown great potential to improve the predictive ability of PCa recurrence. In contrast, predictive biomarkers of recurrence in BCa and RCC have been poorly explored. Overall, this review highlights the great potential of metabolomics in discovering prognostic biomarkers for a more accurate patient risk stratification in urological cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellProstatic NeoplasmsKidney NeoplasmsMaleHumansNeoplasm Recurrence, LocalNeoplasm Grading

Stichwörter der Autor:innen

Bladder cancerMetabolomicsPrognostic biomarkersProstate cancerRecurrenceRenal cell carcinoma

Autor:innen und Institutionen

  • Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory…

Förderung

  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Amaro, F., Carvalho, M., Bastos, M. L., Guedes de Pinho, P., & Pinto, J. (2023). Metabolic signature biomarkers for predicting the recurrence of urological cancers. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2023.117553

Vancouver

Amaro F, Carvalho M, Bastos ML, Guedes de Pinho P, Pinto J. Metabolic signature biomarkers for predicting the recurrence of urological cancers. Clinica Chimica Acta. 2023. doi:10.1016/j.cca.2023.117553

BibTeX
@article{Amaro2023,
  author = {Amaro, Filipa and Carvalho, Márcia and Bastos, Maria de Lourdes and Guedes de Pinho, Paula and Pinto, Joana},
  title = {Metabolic signature biomarkers for predicting the recurrence of urological cancers},
  journal = {Clinica Chimica Acta},
  year = {2023},
  doi = {10.1016/j.cca.2023.117553}
}
Kostenlos starten →